Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 25 Aug 2024
Risankizumab for the treatment of patients with moderately to severely active ulcerative colitis
23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of ...
Posted by Michael Wonder on 22 Aug 2024
Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS
22 August 2024 - Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, ...
Posted by Michael Wonder on 14 Aug 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids (final guidance)
14 August 2024 - NICE has published final evidence-based recommendations on the use of linzagolix choline (Yselty) for the treatment ...
Posted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 10 Aug 2024
Two new treatment options for incurable blood cancer assessed
9 August 2024 - We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 08 Aug 2024
World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England
8 August 2024 - Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time ...
Posted by Michael Wonder on 08 Aug 2024
Vertex announces Casgevy reimbursement agreement for the treatment of transfusion-dependent beta thalassemia in England
7 August 2024 - Eligible transfusion-dependent beta thalassaemia patients in England will be able to access the therapy from today. ...
Posted by Michael Wonder on 07 Aug 2024
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
8 August 2024 - Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating ...
Posted by Michael Wonder on 07 Aug 2024
Durvalumab in combination with chemotherapy before surgery (neo-adjuvant) then alone after surgery (adjuvant) for the treatment of adults with resectable non-small-cell lung cancer
30 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 07 Aug 2024
Burosumab for the treatment of adults with X-linked hypophosphataemia
7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked ...
Posted by Michael Wonder on 07 Aug 2024
Abaloparatide for the treatment of women with osteoporosis after menopause
6 August 2024 - NICE has issued dvidence-based recommendations on the use of abaloparatide (Eladynos) for treatment of osteoporosis after ...
Posted by Michael Wonder on 06 Aug 2024
Maralixibat chloride for the treatment of patients with cholestatic pruritus associated with Alagille syndrome
31 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Aug 2024
How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe
1 August 2024 - This paper elicited the opinions of European stakeholders on how HTA can be improved to facilitate access. ...